Innovation

Model System for Identifying Anti-Cancer Agents That Interfere with Gli2

Wisconsin Alumni Research Foundation (University of Wisconsin)
posted on 06/23/2009

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a mutant form of Gli2 that can be used to screen for agents that interfere with Gli2-mediated tumorigenesis.

Suggested Uses

  • Assays to identify novel inhibitors of Hh signaling, which potentially may provide new treatments for cancer
  • Assays to explore how compounds on the Hh pathway work

Advantages

  • Amenable to high throughput screening
  • May lead to the identification of novel anti-cancer agents

Innovation Details
 

Detailed Description

Cancer accounts for nearly one quarter of the deaths in the U.S. each year. Treatment options include radiation, chemotherapy and surgery, among others. However, these treatments often cause debilitating side effects and are not always efficacious. New ways of treating cancer are needed.

The glioma-associated (GLI) proteins may provide a new drug target for cancer treatment. These proteins are a family of transcription factors involved in the activation of the highly conserved Hedgehog (Hh) signaling pathway in mammals. In particular, Gli2 appears to be the major nuclear effector of Hh signaling. Because activation of this pathway in adult tissues has been implicated in tumorigenesis, agents that inhibit Gli2 may reduce tumor growth.

UW-Madison researchers have developed a mutant form of Gli2 that results in a constitutively active Hh signaling pathway. They identified a point mutation that inhibits the first step in the degradation of Gli2 and makes the protein more stable.

Because the mutation increases the half-life of Gli2, it results in an increase in Gli2-dependent transcription. This in turn leads to an increase in tumorigenesis, which enables high throughput screening for potential anti-cancer compounds that interfere with Gli2-mediated tumor growth.
 

File Number: P07243US 

Other Information:
Bhatia N., Thiyagarajan S., Elcheva I., Saleem M., Dlugosz A., Mukhtar H. and Spiegelman V.S. 2006. Gli2 Is Targeted for Ubiquitination and Degradation by β-TrCP Ubiquitin Ligase. J. Biol. Chem. 281, 19320-19326.

See WARF reference number P08215US for a method of treating prostate cancer by inhibiting the expression of Gli2.


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact Emily Bauer at Wisconsin Alumni Research Foundation (University of Wisconsin) for more information.

request more info
People

Case Manager:

Icon_avatar Emily Bauer

Innovations (130)

Followed By

Follow this innovation



No one is following this innovation.

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

4,055 members 12,267 innovations 109 organizations

Browse

William Garner, M.D., MPH - CEO of Urigen, N.A., Inc.

"The iBridge Network provides an important additional pathway for entrepreneurs to access university innovations that may otherwise have been lost. The transparency of this pathway between entrepreneurs..."  read more...